AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03866239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
Study NCT03041961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia full spectrum
Description: Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
Study NCT03041961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia extract
Description: Powdered extract obtained from aronia berries (Aronia melanocarpa)
Study NCT02431741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H1
Description: LFX453 high dose cream 1
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L1
Description: LFX453 low dose cream 1
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 H2
Description: LFX453 high dose cream 2
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX453 L2
Description: LFX453 low dose cream 2
Study NCT01219166 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic Cholecystectomy
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod
Description: Imiquimod cream
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo cream 1
Study NCT02052687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo cream 2
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study NCT00137423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248 (sunitinib)
Description: 37.5 mg/day, oral, continuous daily dosing
Study NCT03438812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone (DHEA)
Description: Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
Study NCT00811473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Oral treatment with 150 up to 300 mg/day once daily in the evening
Study NCT00811473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment once daily in the evening
Study NCT06759688 — intervention group
Intervention type: BEHAVIORAL
Intervention: Carbohydrates restriction
Description: Patients followed a low carbohydrate dietary approach (LCDs). It means lower than 130 grams carbohydrates per day with special restriction restrictions on:~* Artificial sugars (e.g., sweets, baked goods, pasta, bread).~* Also, rice, butter made from vegetable oils and all types of oils except olive oil.~They were allowed:~* All types of fresh fruits and vegetable.~* Boiled potatoes.
Study NCT01133626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered daily for 42 days of treatment
Study NCT01133626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered daily for 42 days of treatment
Study NCT01133626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone capsules
Description: Prednisone 10 mg capsule taken each day on the last 7 days of treatment
Study NCT01133626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Prednisone Capsules
Description: Placebo prednisone capsule taken each day on the last 7 days of treatment
Study NCT01133626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prednisone Capsules
Description: Placebo prednisone capsule taken each day on the last 7 days of treatment
Study NCT01133626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
Study NCT01126658 — intervention group
Intervention type: OTHER
Intervention: drainage of cerebrospinal fluid (CSF)
Description: Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
Study NCT02851407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Study NCT02851407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Study NCT03217084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI varnish GC
Description: MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
Study NCT03217084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: White varnish 3M
Description: White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
Study NCT00970814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BBCET
Description: 11 BBCET sessions
Study NCT00970814 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BBCET
Description: 11 BBCET Sessions
Study NCT00970814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam XR
Description: 500mg - 2000mg Once per day 16 weeks
Study NCT00970814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 500mg - 2000mg Once per day 16 weeks
Study NCT01867957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose GC1109
Description: 50ug/dose
Study NCT01867957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose GC1109
Description: 100ug/dose
Study NCT01867957 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose Placebo
Description: 0.9% Saline 0.5 mL
Study NCT01867957 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose Placebo
Description: 0.9% Saline 1.0 mL
Study NCT01990430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer.
Study NCT00119912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A 1 Intervention arm Flex Sig
Description: Screening by flexible sigmoidoscopy
Study NCT00119912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A 2 Intervention arm Flex Sig + iFOBT
Description: In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
Study NCT00730912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
Study NCT00730912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: loratadine 10 mg tablet once daily for 4 weeks
Study NCT00732615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection
Study NCT00732615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
Study NCT04382625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
Study NCT02360644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
Study NCT03586856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal mask interface
Description: Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
Study NCT03586856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal prongs interface
Description: Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
Study NCT03637166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT03637166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT00003492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT04993989 — intervention group
Intervention type: DRUG
Intervention: Iberogast (STW5, BAY98-7411)
Description: Survey without any intervention assigned in the study.
Study NCT01516424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blonanserin
Description: Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
Study NCT01516424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
Study NCT02100059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
Study NCT00670865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic discharge summary system
Description: The customized electronic discharge summary program will be used to generate patient discharge summaries.
Study NCT04429737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: clam protein capsules
Description: The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
Study NCT04429737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clam peptide plus Chlorella capsules
Description: The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
Study NCT04429737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
Study NCT02653807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement
Description: manual therapy intervention
Study NCT02653807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic mobilization
Description: manual therapy intervention
Study NCT04446377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apilimod Dimesylate Capsule
Description: LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
Study NCT04446377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose in Swedish orange, Size 0 capsules
Study NCT01840709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
Study NCT02250755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI T1 T2 sequences
Description: MRI
Study NCT01890551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic kine-mri
Description: Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
Study NCT00278655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study NCT03739606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD123/CD3 Monoclonal Antibody MGD006
Description: Given IV
Study NCT01972906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: apply moxibustion according to traditional Chinese medicine
Study NCT01972906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Sustained Release Capsules
Description: apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 70 mg
Description: single dose
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Description: single dose
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Repeat dose, once daily for 3 days
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Description: Repeat dose, twice daily for 3 days
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Description: Repeat dose, TIDfor 3 days
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 630 mg
Description: Repeat dose, twice daily for 3 days
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 70 mg + Ritonavir 100mg
Description: single dose, day 1
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 210 mg + Ritonavir 100mg
Description: single dose, day 1
Study NCT01332552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2485852 210 mg +Ritonavir 100mg
Description: single dose daily for 3 days
Study NCT00729898 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT04224415 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: C225+CPT-11
Description: Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1
Study NCT03292406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non active ingredients of CD11301
Study NCT03292406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD11301 0.03%
Description: Topical Gel
Study NCT03292406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD11301 0.06%
Description: Topical Gel
Study NCT06368999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG
Description: registration of 8 minutes of EEG
Study NCT03840096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Flex
Description: All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
Study NCT04654390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP16001 Amg
Description: Tablets, Orally, Once daily
Study NCT04654390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Amg
Description: Tablets, Orally, Once daily
Study NCT03803150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRA approach
Description: A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
Study NCT03803150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RT approach
Description: The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
Study NCT02409043 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood drawn for comparison with other groups
Study NCT02409043 — intervention group
Intervention type: OTHER
Intervention: Stroke blood draw
Description: Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
Study NCT02405000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative CT imaging
Description: Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
Study NCT00022672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab (Herceptin®)
Description: 4mg/kg iv loading dose, followed by 2mg/kg iv weekly